. 2024 Aug 30;16(8):e68249. doi: 10.7759/cureus.68249

Table 3. Factors associated with failure of SVR.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TB, total bilirubin; HCV, hepatitis C virus; EVR, early virological response; SVR, sustained virological response; SD, standard deviation; RNA, ribonucleic acid; RF, reference group.

Note: ^a Data is presented as mean± SD, while ^b data is presented as n (%).

P-values of < 0.05 were considered significant.

Independent variable	Subgroups	SVR achieved (N=46)	SVR not achieved (N=7)	OR (95% CI)	p-value
Age^a	Mean ±SD	47.9 ±15.2	63.7 ±6.7	1.13 (1.03-1.30)	0.009
Pretreatment ALT (IU/L)^a	Mean (SD)	39.5 (19.8)	40.1 (12.2)	1.00 (0.95-1.04)	0.931
Pretreatment AST (IU/L)^a	Mean (SD)	37.0 (22.3)	37.9 (20.7)	1.00 (0.96-1.04)	0.920
Pretreatment TB (mg/dL)^a	Mean (SD)	0.8 (0.2)	0.8 (0.2)	6.84 (0.04-3347.26)	0.498
Pretreatment ALP (IU/L)^a	Mean (SD)	3.6 (0.4)	3.4 (0.5)	0.31 (0.04-1.88)	0.205
Gender^b	Male	16 (34.8)	1 (14.3)	RF	0.517
Gender^b	Female	30 (65.2)	6 (85.7)	3.20 (0.49-63.22)	0.517
Liver cirrhosis^b	Noncirrhotic	37 (80.4)	3 (42.9)	RF	0.031
Liver cirrhosis^b	Cirrhosis	9 (19.6)	4 (57.1)	5.48 (1.04-28.98)	0.031
Hypertension^b	No	39 (84.8)	5 (71.4)	RF	0.737
Hypertension^b	Yes	7 (15.2)	2 (28.6)	2.23 (0.28-12.90)	0.737
Diabetes ^b	No	38 (82.6)	3 (42.9)	RF	0.019
Diabetes ^b	Yes	8 (17.4)	4 (57.1)	6.33 (1.19-37.93)	0.019
Fatty liver^b	No	38 (82.6)	7 (100.0)	RF	0.528
Fatty liver^b	Yes	8 (17.4)	0 (0.0)	1.03 (0.28-2.90)	0.528
Pretreatment Viral load (HCV RNA, log10 IU/mL)^a	Mean ±SD	2340003.5± 4963738.0	59672003.7±93476406.8	2.27(0.45-12.73)	<0.001
EVR^b	Yes	46 (100.0)	5 (71.4)	RF	0.009
EVR^b	Not	0 (0.0)	2 (28.6)	7.63(-3.77- 17.78)	0.009